Find Clinical Trial
INES – Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.
← Back
| Study Phase |
Phase 1 |
| Therapeutic Area |
Cancers |
| Indication | Solid tumors |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
LUCITANIB, |
| Active Substance Code | S080881 |
| Protocol Code | CL1-80881-002 |
| EudraCT Code | 2013-001520-19 |
| ISRCTN Code | ISRCTN23201971 |
Documents and links
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
